Generic Assays GmbH was established in 2002 by Professor Dr. Dirk Roggenbuck. The company is located in Dahlewitz, south of Berlin.

Generic Assays focuses primarily on products for autoimmune disease research.

Generic Assays is a company that faces the challenges of the market and presents you with a partner who purposefully engaged in the development of new market-relevant products.

Here, innovation and quality are of prime importance, without neglecting cost-effectiveness. These new developments are often carried out in cooperation with academic institutions or routine laboratories e.g. Charité Berlin, Technical University of Dresden or with foreign partners.

For example, the Anti-Ganglioside Dot for the diagnosis of polyneuropathy won a technology transfer prize from the Land Brandenburg in 2005.

For the identification of the main antigen glycoprotein 2 (GP2), for the differential diagnosis of Crohn’s disease, Generic Assays was honored by the IHK Potsdam with the Innovation Award of 2010.